Navigation Links
Abattis Signs LOI With Crudessence Kombucha Inc. To License Infused, Blended Kombucha Tea
Date:3/6/2013

VANCOUVER, British Columbia, March 6, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has signed a letter of intent with Crudessence Kombucha Inc. ("RISE") to acquire the worldwide exclusive license "the License" to produce, distribute, market and sell a Kombucha tea infused or blended with additional nutraceutical and bioceutical formulas developed and owned by Abattis and its subsidiaries. Under the Terms of the Agreement will acquire "the License" in exchange for 500,000 shares of Abattis at a deemed price of CAD $0.20 and a running technology royalty fee to "RISE".

Rise Kombucha is a highly successful brand sold across Canada, the purpose of the LOI is to enable Abattis to initially bring a new brand of Cannabidiol CBD infused probiotic functional beverages to the markets starting in Washington and Colorado, the brand will be launched as "Cannabucha Sun Rise™" this product will be the first of its kind with infused Cannabidiol "CBD" with the probiotic effects to create one of the best possible health drinks in the world. Kombucha is a microbial culture of various bacteria and yeast species. Fermentation of the culture in naturally sweetened tea produces numerous organic acids such as ascetic acid, gluconic acid, malic acid, amino acids and enzymes, and polyphenols (e.g. catechins) that improve overall health.

Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are very excited to enter into the emerging US CBD infused product markets, leading with a Kombucha beverage which is fast growing in popularity. Kombucha is a perfect delivery beverage for CBD's because it is a functional probiotic drink that strengthens the immune system, balances intestinal flora, stimulates digestion, combats stress, and increases energy."  Mr. Withrow went on to say, "With Mr. Tim Fealey , former Executive VP of Product Development for The Coca Cola Company and as our VP of Product Development we are able to ensure we achieve all of the necessary goals to make this a huge success in the markets we address."

About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

About Crudessence and Rise Kombucha.

RISE is a young rapidly growing company committed to offering living, sparkling tea beverages. In harmony with nature, our kombucha not only tastes good but also is the perfect adjunct to good health. RISE is a brand that is in sync with the evolution of society. By combining the best in natural health and the best scientific research available, we offer a delicious, healthy and affordable whole food beverage.

ON BEHALF OF THE BOARD

" Michael Withrow "                                                                        
Michael Withrow , President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

 

Contact: Nick Brusatore , +1-604-356-0411, nbrusatore@gmail.com


'/>"/>
SOURCE Abattis Bioceuticals Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
2. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
3. Aviir Signs Distribution And Expansion Pact Covering 19 Middle Eastern And North African Countries
4. Aviir Signs Distribution and Expansion Pact Covering 19 Middle Eastern and North African Countries
5. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
6. AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program for Cancer
7. Deborah Morosini, MD Pathologist and Patient Advocate Signs on as Medical Director and Advisory Board Member of Store-A-Tooth™ Dental Stem Cell Banking
8. Trade Show Display Co. GLM Displays Redesigns Blog
9. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
10. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
11. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... -- Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the US, ... World. Annual estimates and forecasts are provided for the period 2015 ... markets. Market data and analytics are derived from primary and secondary ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart IOT ... to get under way for the framework, which is designed to reduce the use ... to be transferred eventually to other industries that also require efficient IoT and management ...
(Date:2/16/2017)... PARK, Calif. and GREENWICH, ... Capital, a private investment firm focused on venture ... announced the promotion of Josh Richardson , ... focuses on investments in biotechnology companies.  He is ... has played important roles in Longitude,s investments in ...
Breaking Biology Technology:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):